加载中
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
收盘时
US$19.15
−US$0.40 · -2.05%
盘后
US$19.01
−US$0.14 · -0.73%
10月12日 19:48 ET
盘中时间采用ET。市场数据可能有所延迟。
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
日内区间
当前US$19.15
52周区间
当前US$19.15
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 694.1万 USD | 904.1万 USD | 1401.8万 USD | — | — |
| 销货成本 | 295.5万 USD | — | — | — | — |
| 毛利 | 398.6万 USD | 904.1万 USD | 1401.8万 USD | — | — |
| 研究与开发 | 1.74亿 USD | 1.3亿 USD | 2308.9万 USD | 2327.2万 USD | 1411万 USD |
| 销售、一般及管理费用 | 4376.8万 USD | 3295.5万 USD | 1965.7万 USD | 1362.9万 USD | 1109.4万 USD |
| 营业费用 | 2.18亿 USD | 3.15亿 USD | 1.24亿 USD | 3690.1万 USD | 2520.4万 USD |
| 利息收入 | 1171.9万 USD | 1283.7万 USD | 272.4万 USD | 5000 USD | 1万 USD |
| 利息支出 | — | — | — | 5000 USD | 1万 USD |
| 折旧和摊销 | 295.5万 USD | 210.2万 USD | 72.8万 USD | 63.1万 USD | 75.5万 USD |
| 营业利润 | −2.14亿 USD | −3.06亿 USD | −1.1亿 USD | −3690.1万 USD | −2520.4万 USD |
| 净利润 | −2.12亿 USD | −2.93亿 USD | −1.07亿 USD | −3689.6万 USD | −2471.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$33.00
上涨空间 72.32%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8865.93万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM5383.39万0.07%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI3755.79万0.38%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF3393.48万0.03%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1904.98万0.14%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO1660.69万0.09%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA1169.86万0.05%218.24亿 USD0.03%US$32.66-0.40%
Vanguard Health Care ETFVHT805.53万0.04%220亿 USD0.09%US$320.67+0.52%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
